期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

活化性受体NKG2D免疫监视作用研究新进展 被引量：1

下载PDF
导出
摘要 近年来,人们对活化性受体NKG2D免疫监视作用有了新的认识,包括其配体为压力诱导型分子,在应激如感染,细胞变异等条件下诱导表达,这为临床肿瘤免疫治疗提供了一种新的疗法——NKG2D及其配体介导的肿瘤免疫治疗。
作者 程妮 韩福才
机构地区 山西医科大学第二医院 山西省肿瘤医院呼吸内科
出处 《中国药物与临床》 CAS 2010年第8期900-901,共2页 Chinese Remedies & Clinics
关键词 NKG2D 免疫监视 受体 活化 肿瘤免疫治疗 诱导表达 细胞变异 诱导型
分类号 R730.5 [医药卫生—肿瘤]
  • 相关文献

参考文献13

  • 1高忠,冯刚.NKG2D及其配体的免疫调节[J].中国实验诊断学,2008,12(8):1067-1068. 被引量：2
  • 2Choi BK,Kim YH,Kang WJ,et al.Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and-CD4 therapy.Cancer Res,2007,67:8891-8899.
  • 3Jan Chalupny N,Sutherland CL,Lawrence WA,et al.ULBP4 is a novel ligand for human NKG2D.Biochem Biophys Res Commun,2003,305(1):129.
  • 4Eagle RA,Flack G,Warford A.Cellular expression,trafficking,and funotion of two isoforms of human ULBP5/RAET1G.PloS ONE,2009,4(2):1371-1384.
  • 5Holdenrieder S A,Sfieber P,Peterfi A,et al.Soluble MICB in malignant diseases:analysis of diagnostic significance and correlation with soluble MICA.Cancer Immunol Immunother,2006,55:1584.
  • 6Buhtoiarov IN,Rakhmilevich AL,Lanier LL,et al.Naive mouse macrophagns becone activated following recognition of L5178Y lymphoma cells via concurrent ligation of CD40,NKG2D,and CD18 molecules.J Immunol,2009,182(4):1940-1953.
  • 7Whang MI,Guerra N,Raulet DH.Costimulation of dendritic epidermal gammadelta T cells by a new NKG2D ligand expressed specifically in the skin.J Immunol,2009,182(8):4557-4564.
  • 8邬鹏,魏海明,田志刚.IL-2促进PBMC来源的NK、NKT、CD8^+ T细胞高表达NKG2D[J].中华微生物学和免疫学杂志,2006,26(8):684-687. 被引量：3
  • 9Boyiadzis M,Memon S,Carson J,et al.Up-regulation of NK cell activating receptors folloeing allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels.Biol Blood Marrow Transplant,2008,14(3):290-300.
  • 10Strbo N,de Armas L,Liu H,et al.IL-21 augments natural killer effector functions in chronically HIV-infected individuals.AIDS,2008,22(13):1551-1560.

二级参考文献27

  • 1Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol, 2003, 3 (10): 781-790.
  • 2Groh V, Wu J, Yee C, et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature, 2002, 419(6908) : 734-738.
  • 3Wu JD, Higgins LM, Steinle A, et al. Prevalent expression of the immunostimulatory MHC class Ⅰ chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest, 2004, 114(4): 560-568.
  • 4Coudert JD, Zimmer J, Tomasello E, et al. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood, 2005, 106(5): 1711-1717.
  • 5Rosenberg SA, Mule JJ, Spiess PJ, et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med, 1985,161(5): 1169-1188.
  • 6Lafreniere R, Rosenberg SA. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (rIL-2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J Immunol, 1985,135(6) : 4273-4280.
  • 7Lu PH, Negrin ItS. A novel population of expanded human CD3^+ CD56^+ cells derived from T cells with potent in vivo antiturnor activity in mice with severe combined immunedeficiency. J Immunol, 1994, 153(4) : 1687-1696.
  • 8Mule JJ, Shu S, Rosenberg SA. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol,1985, 135(1): 646-652.
  • 9Salih HR, Rammensee HG, Steinle A. Cutting edge : down-regulation of MICA on human tumors by proteolytic shedding. J Immunol, 2002, 169(8) : 4098-4102.
  • 10Ogasawara K, Hamerman JA, Hsin H, et al. Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity, 2003, 18(1) :41-51.

共引文献3

同被引文献4

引证文献1

二级引证文献1

中国药物与临床
2010年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部